The JAK1/2 inhibitor ruxolitinib downregulates the immune checkpoint protein B7H3 in multiple myeloma.
Ning XuErin YuNicole NgMingjie LiSean BujarskiAva HekmatiIsabella NassirTara HekmatiJanna YuDavid DanielyCathy S WangClara KimHaiming ChenJames R BerensonPublished in: Hematological oncology (2022)
We hypothesized that ruxolitinib may inhibit the immune checkpoint protein, B7H3; and, thus, investigated its effects on this immune inhibitor using multiple myeloma (MM) cell lines, bone marrow (BM) mononuclear cells from MM patients and human MM LAG λ -1A xenografts. Ruxolitinib reduced B7H3 gene and protein expression and increased IL-2 and CD8 gene expression. These results suggest that ruxolitinib inhibition of B7H3 may restore exhausted T-cell activity in the MM BM tumor microenvironment.
Keyphrases
- multiple myeloma
- gene expression
- bone marrow
- end stage renal disease
- ejection fraction
- endothelial cells
- newly diagnosed
- chronic kidney disease
- dna methylation
- protein protein
- mesenchymal stem cells
- prognostic factors
- genome wide
- peritoneal dialysis
- peripheral blood
- copy number
- high resolution
- small molecule
- pluripotent stem cells